{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8","upperLimit":"90.6","value":"33.3"},{"groupId":"OG001","lowerLimit":"2.5","upperLimit":"100.0","value":"100.0"},{"groupId":"OG002","lowerLimit":"42.1","upperLimit":"99.6","value":"85.7"},{"groupId":"OG003","lowerLimit":"26.2","upperLimit":"87.8","value":"60.0"},{"groupId":"OG004","lowerLimit":"26.2","upperLimit":"87.8","value":"60.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants with a best overall response of partial response (PR), very good PR (VGPR), complete response (CR), or stringent CR (sCR) based on the International Myeloma Working Group Uniform Response Criteria.\n\nPR: ≥ 50% reduction of serum M-protein and ≥90% reduction in urine M-protein or to \\< 200 mg/24 hrs, or a ≥50% decrease in the difference between involved and uninvolved free light chain levels (dFLC). A ≥ 50% decrease in the size of soft tissue plasmacytomas present at baseline.\n\nVGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% decrease in serum M-protein with urine M-protein \\<100 mg/24 hrs. If disease measurable only by serum FLC (SFLC), ≥ 90% decrease in dFLC.\n\nCR: No immunofixation on serum and urine, disappearance of soft tissue plasmacytomas and \\<5% plasma cells in bone marrow (BM). Normal SFLC ratio if disease measurable only by SFLC.\n\nsCR: As for CR, and absence of clonal plasma cells in BM.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg/day on days 1 to 21 and dexamethasone 20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Oprozomib 150 mg 5/14 + Pomalidomide 4 mg + Dexamethasone"},{"description":"Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with pomalidomide 2 mg/day on days 1 to 21 and dexamethasone 20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.","id":"OG001","title":"Oprozomib 150 mg 5/14 + Pomalidomide 2 mg + Dexamethasone"},{"description":"Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.","id":"OG002","title":"Oprozomib 210 mg 2/7 + Pomalidomide 4 mg + Dexamethasone"},{"description":"Participants received oprozomib 240 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.","id":"OG003","title":"Oprozomib 240 mg 2/7 + Pomalidomide 4 mg + Dexamethasone"},{"description":"Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.","id":"OG004","title":"Oprozomib 210 mg 2/7 + Pomalidomide 4 mg + Dexamethasone: Expansion Phase"}],"paramType":"NUMBER","populationDescription":"Participants who received at least 1 dose of any study drug","reportingStatus":"POSTED","timeFrame":"Disease response was assessed every 4 weeks for the first 18 months and then every 8 weeks for the remainder of study treatment; median duration of treatment was 7.6, 28.0, 32.1, 46.3, and 17.4 weeks in each treatment group, respectively.","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}